Columbia Laboratories Events Calendar

   Events Date Time
CBRX Q1 2013 Financial Results Conference Call  
  • (877) 303-9483 (U.S. & Canada) or (760) 666-3584
  • Conference ID: 52824557
  • Webcast
  • 05/09/2013 11:00am EDT
       Archived Events     Date Replay Until
    CBRX Q4 & YE 2012 Financial Results Conference Call 03/14/2013 03/14/2014
    CBRX presentation at 33rd Annual Cowen and Company Health Care Conference 03/06/2013 TBA
    CBRX Q3 2012 Financial Results Conference Call 11/08/2012 11/08/2013
    CBRX Q2 2012 Financial Results Conference Call  08/08/2012 08/08/2013

    The previously-recorded webcasts included in this "Events" section are provided as a service to investors and other interested parties. They contain forward-looking statements, which statements are indicated by the words “may,” “will,” “plans,” “believes,” “expects,” “anticipates,” “potential,” “should,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. Factors that might cause future results to differ include, but are not limited to, the following: Actavis' and Merck Serono's success in marketing CRINONE for use in infertility in their respective markets; successful development by Actavis of a next-generation vaginal progesterone product for the U.S. market; difficulties or delays in manufacturing; the availability and pricing of third-party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to manufacturing facilities, products and/or businesses; changes in the laws and regulations; the ability to obtain and enforce patents and other intellectual property rights; the impact of patent expiration; the impact of competitive products and pricing; the cost of evaluating potential strategic transactions; the cost of the Company's pending relocation to Boston; Columbia’s ability to timely regain compliance with the Nasdaq minimum closing bid price rule; the strength of the United States dollar relative to international currencies, particularly the euro; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the SEC. Columbia does not undertake any responsibility to revise or update any forward-looking statements contained herein.